Search for: "CHANG v. WYETH" Results 1 - 20 of 544
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 Dec 2023, 7:58 am by Timothy Bonis
The Federal Circuit demanded full scope enablement in biological and chemical fields before Amgen (see Wyeth & Cordis Corp. v. [read post]
The judge reviewed the national case law on selections/deletions from multiple lists (Merck v Shionogi [2016] EWHC 2989 (Pat), Nokia v IPCom [2012] EWCA Civ 567 and GlaxoSmithKline v Wyeth [2016] EWHC 1045 (Pat)) and the EPO cases reviewed therein and in the EPO Case Law Book. [read post]
28 May 2020, 5:29 am by Schachtman
This is true whether the step completely changes a reliable methodology or merely misapplies that methodology. [read post]
23 May 2019, 9:30 pm by Alana Bevan
Supreme Court ruled that judges rather than juries should determine whether or not pharmaceutical product liability claims may proceed under the “clear evidence” standard established in Wyeth v. [read post]
3 Apr 2019, 6:21 am by Matthew Scott Johnson
Kirksey is cited in the following article: Charles Calleros & Val Ricks, Kirksey v. [read post]
27 Mar 2019, 1:00 am by Thaddeus Mason Pope, JD, PhD
McCabe, Indiana University, Transgender Rights in the Days of Changing Regulatory Interpretations: Where Are We Now and What is Needed? [read post]
8 Jan 2019, 6:32 am by Elizabeth McCuskey
Direct discussion of the “clear evidence” standard used to resolve ambiguity in impossibility pre-emption, derived from the Supreme Court’s decision in Wyeth v. [read post]
10 Jul 2018, 6:21 pm by Adam Feldman
The facts are different in the cases, the court of appeals is constrained by precedent in a different way than the Supreme Court, and the legal parameters changed in the time between the two decisions. [read post]
18 Sep 2017, 11:12 am by Tom Lamb
Its ruling is the latest in a series of plaintiff-friendly decisions that misconstrued the Supreme Court’s landmark 2009 ruling in Wyeth Inc. v. [read post]